Please use this identifier to cite or link to this item:
Title: Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial
Author: Willemse, Sean W.
Roes, Kit C. B.
Van Damme, Philip
Hardiman, Orla
Ingre, Caroline
Povedano Panades, Mónica
Wray, Naomi R.
Gijzen, Marleen
De Pagter, Mirjam S.
Demaegd, Koen C.
Janse, Annemarie F. C.
Vink, Roel G.
Sleutjes, Boudewijn T. H. M.
Chiò, Adriano
Corcia, Philippe
Reviers, Evy
Al-Chalabi, Ammar
Kiernan, Matthew C.
Van Den Berg, Leonard H.
Van Es, Michael A.
Van Eijk, Ruben P. A.
Keywords: Esclerosi lateral amiotròfica
Assaigs clínics
Amyotrophic lateral sclerosis
Clinical trials
Issue Date: 5-Dec-2022
Publisher: Springer Science and Business Media LLC
Abstract: BackgroundGiven the large genetic heterogeneity in amyotrophic lateral sclerosis (ALS), it seems likely that genetic subgroups may benefit differently from treatment. An exploratory meta-analysis identified that patients homozygous for the C-allele at SNP rs12608932, a single nucleotide polymorphism in the gene UNC13A, had a statistically significant survival benefit when treated with lithium carbonate. We aim to confirm the efficacy of lithium carbonate on the time to death or respiratory insufficiency in patients with ALS homozygous for the C-allele at SNP rs12608932 in UNC13A. MethodsA randomized, group-sequential, event-driven, double-blind, placebo-controlled trial will be conducted in 15 sites across Europe and Australia. Patients will be genotyped for UNC13A; those homozygous for the C-allele at SNP rs12608932 will be eligible. Patients must have a diagnosis of ALS according to the revised El Escorial criteria, and a TRICALS risk-profile score between -6.0 and -2.0. An expected number of 1200 patients will be screened in order to enroll a target sample size of 171 patients. Patients will be randomly allocated in a 2:1 ratio to lithium carbonate or matching placebo, and treated for a maximum duration of 24 months. The primary endpoint is the time to death or respiratory insufficiency, whichever occurs first. Key secondary endpoints include functional decline, respiratory function, quality of life, tolerability, and safety. An interim analysis for futility and efficacy will be conducted after the occurrence of 41 events. DiscussionLithium carbonate has been proven to be safe and well-tolerated in patients with ALS. Given the favorable safety profile, the potential benefits are considered to outweigh the burden and risks associated with study participation. This study may provide conclusive evidence about the life-prolonging potential of lithium carbonate in a genetic ALS subgroup.
Note: Reproducció del document publicat a:
It is part of: Trials, 2022, vol. 23, num. 1, p. 978
Related resource:
ISSN: 1745-6215
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s13063-022-06906-5.pdf1.26 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons